INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers

Alec G. Trub¹, John E. Bisi¹, Catherine Dietrich², Michael Taylor, Jay C. Strum¹, Shom Goel², Patrick J. Roberts^1
1Incyclix Bio, Durham, NC, United States, ²The Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia